2 min
National Cancer Research Month: Baylor Researchers at Forefront of New Discoveries
May is National Cancer Research Month, which highlights the importance of lifesaving research to the millions of people around the world affected by cancer. Thanks to spectacular advances made by cancer researchers, approximately 18.6 million people in the United States and millions more worldwide are living with, through and beyond their disease. Over the past year, Baylor University Media and Public Relations has reported on Baylor research at the forefront of discovering novel approaches to effective cancer therapies. University researchers are using tumor starvation techniques, natural products, phages, modified bacteria, precision nutrition and more in their trailblazing work on some of the most aggressive cancers, including kidney, pancreatic, oral, colorectal and breast cancers. In a recent article published by the University, it featured the hard work and research of eight Baylor experts driving those discoveries forward: • Kevin G. Pinney is developing a next-generation treatment for kidney cancer that targets the blood vessels feeding tumors. His research focuses on specialized drug conjugates designed to cut off oxygen and nutrients to renal cell carcinoma tumors — essentially starving cancer cells to death. • Daniel Romo is accelerating new therapies for pancreatic cancer using compounds derived from marine natural products. His work on a simplified version of pateamine A could offer a new therapeutic pathway for pancreatic ductal adenocarcinoma, one of the most aggressive and difficult-to-treat cancers. • Joseph Taube is investigating how breast cancers spread and resist treatment. His recent work examines whether a natural compound called Ophiobolin A can trigger inflammatory forms of cancer cell death that may work alongside immunotherapy — particularly in treatment-resistant triple-negative breast cancers. • Leigh Greathouse is combining cancer biology, nutrition science, and AI to personalize cancer prevention and treatment strategies. Her research explores how diet and the gut microbiome influence cancer outcomes and survivorship. • Michael S. VanNieuwenhze is leading groundbreaking colorectal cancer research using modified bacteria to deliver cancer-killing proteins directly into tumor cells. His team is engineering Listeria monocytogenes as a targeted therapeutic delivery system. • Aaron Wright is helping lead a major ARPA-H initiative exploring the use of bacteriophages — viruses that attack bacteria — to reshape the human microbiome and improve health. The project could eventually help prevent diseases linked to oral and colorectal cancers through low-cost phage-based treatments. • Savannah Rauschendorfer is researching how exercise interventions may reduce the harmful cardiac side effects of chemotherapy in adolescent and young adult cancer patients. Her work aims to identify patients at risk of cardiotoxicity earlier and improve long-term survivorship outcomes. • Jonathan Kelber studies the cellular and molecular mechanisms behind aggressive breast and pancreatic cancers. Through his Developmental Oncogene Laboratory, Kelber investigates how cancer cells evolve during tumor progression and tissue regeneration. Together, these researchers showcase how cancer science is rapidly evolving beyond traditional treatments – integrating biology, chemistry, nutrition, exercise science, microbiome research, and artificial intelligence in the search for more effective and personalized therapies.




